Published online before print August 7, 2006, doi: 10.1161/CIRCULATIONAHA.106.618918
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:623-629.)
© 2006 American Heart Association, Inc.
Coronary Heart Disease |
Adiponectin and Coronary Heart Disease
A Prospective Study and Meta-Analysis
From the University Department of Vascular Biochemistry, Glasgow, Scotland (N.S., L.C., A.M.W.); Department of Primary Care and Population Sciences, Royal Free UCL Medical School, London, England (G.W., J.T.); Department of Public Health and Primary Care, University of Cambridge, Cambridge, England (N.S., J.D.); and Division of Community Health Sciences, St George’s, University of London, London, England (P.H.W.).
Correspondence to Naveed Sattar, MD, University of Glasgow, 4th Floor QEB, Glasgow Royal Infirmary, G31 2ER, UK. E-mail nsattar{at}clinmed.gla.ac.uk
Received February 6, 2006; revision received June 14, 2006; accepted June 15, 2006.
Background— There is uncertainty about the association between circulating concentrations of adiponectin and coronary heart disease (CHD) risk. We report new data from a prospective study in the context of a meta-analysis of previously published prospective studies.
Methods and Results— We measured baseline adiponectin levels in stored serum samples of 589 men with fatal CHD or nonfatal myocardial infarction and in 1231 controls nested within a prospective study of 5661 men (aged 40 to 59 years) recruited during 1978–1980, as well as in paired samples obtained 4 years apart from 221 of these participants. Baseline adiponectin concentrations correlated (P<0.0001) positively with HDL cholesterol (r=0.33) and inversely with C-reactive protein (r=–0.11) and BMI (r=–0.21), and the year-to-year consistency of adiponectin values was comparable to those of blood pressure and total cholesterol levels. No significant difference between median adiponectin levels at baseline was observed between cases and controls (10.2 versus 10.8 µg/mL; P=0.5), despite the fact that body mass index, HDL, and C-reactive protein were all significant predictors of events in this cohort. The odds ratio for CHD was 0.89 (95% CI, 0.67 to 1.18) in a comparison of men in the top third of adiponectin concentrations compared with those in the bottom third, similar to a meta-analysis (including the present study) of 7 prospective studies involving a total of 1318 CHD cases (odds ratio, 0.84 [95% CI, 0.70 to 1.01]).
Conclusions— In contrast to the strong associations previously reported between adiponectin levels and risk of type 2 diabetes, any association with CHD risk is comparatively moderate and requires further investigation.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease Eur. Heart J., May 2, 2008; 29(10): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Empana Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun Eur. Heart J., May 2, 2008; 29(10): 1221 - 1223. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sattar, P. Watt, L. Cherry, S. Ebrahim, G. Davey Smith, and D. A. Lawlor High Molecular Weight Adiponectin Is Not Associated with Incident Coronary Heart Disease in Older Women: A Nested Prospective Case-Control Study J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1846 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Marso, S. K. Mehta, A. Frutkin, J. A. House, J. R. McCrary, and K. R. Kulkarni Low Adiponectin Levels Are Associated With Atherogenic Dyslipidemia and Lipid-Rich Plaque in Nondiabetic Coronary Arteries Diabetes Care, May 1, 2008; 31(5): 989 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fasshauer, T. Waldeyer, J. Seeger, S. Schrey, T. Ebert, J. Kratzsch, U. Lossner, M. Bluher, M. Stumvoll, R. Faber, et al. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function Eur. J. Endocrinol., February 1, 2008; 158(2): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Nagel, K. Rapp, M. Wabitsch, G. Buchele, A. Kroke, I. Zollner, S. K. Weiland, and W. Koenig Prevalence and Cluster of Cardiometabolic Biomarkers in Overweight and Obese Schoolchildren: Results from a Large Survey in Southwest Germany Clin. Chem., February 1, 2008; 54(2): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Wannamethee, P. H. Whincup, L. Lennon, and N. Sattar Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure Arch Intern Med, July 23, 2007; 167(14): 1510 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Knudson, G. M. Dick, and J. D. Tune Adipokines and Coronary Vasomotor Dysfunction Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Menzaghi, V. Trischitta, and A. Doria Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease Diabetes, May 1, 2007; 56(5): 1198 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon, M. B. Schulze, and E. B. Rimm Letter by Pischon et al Regarding Article, "Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis" Circulation, March 13, 2007; 115(10): e322 - e322. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, L. Cherry, A. M. Wallace, G. Wannamethee, J. Tchernova, N. Sarwar, J. Danesh, and P. H. Whincup Response to Letter Regarding Article, "Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis" Circulation, March 13, 2007; 115(10): e323 - e323. [Full Text] [PDF]
|
|